In this episode of S&C’s Critical Insights podcast, Matthew Hurd, a leader of the Firm’s pharma and life science practice, and& Sophie Vandergrift, a leader of the Firm’s antitrust in this area, discuss hot antitrust topics in healthcare M&A. They explore how pharmaceutical and biotech combinations are likely to be affected by the Biden/Harris administration’s approach to antitrust. They also discuss the antitrust reform bill recently introduced by Senator Amy Klobuchar.
Subscribe to stay current on S&C Insights.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.